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Abstract
Historically landmark experiments showed that capsule switching is critical for Streptococcus
pneumonia survival. Further studies demonstrated that capsule ‘transformation’ occurs via DNA
uptake. In this issue of Cell Host and Microbe, Bikard et al. (2012) show that CRISPR-Cas
systems inhibit DNA uptake, selecting for the outgrowth of CRISPR-defective pneumococci.
To take up DNA or not to take up DNA – that is the question. Each microbe must balance
the need to acquire new beneficial traits by horizontal gene transfer (HGT) with the need to
prevent the entry of genetic elements that impose fitness costs (Levin, 2010). One system
allowing microbes to limit the entry of costly genetic elements is the CRISPR-Cas adaptive
immune system found in many bacteria and archaea (Wiedenheft et al., 2012). CRISPR-Cas
systems have been shown to inhibit DNA uptake by phage infection, plasmid conjugation,
and artificial transformation (Barrangou et al., 2007; Marraffini and Sontheimer, 2008;
Wiedenheft et al., 2012). For the 90% of archaea and 50% of bacteria that maintain
CRISPR-Cas systems (Wiedenheft et al., 2012), there are apparently more benefits to
inhibiting DNA uptake than to promoting it.
Named because they are recognized in microbial genomes as cassettes of Clustered
Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas)
genes, CRISPR-Cas systems have been the subject of a number of recent studies
(Wiedenheft et al., 2012). These investigations have shown that when a microbial genome
containing CRISPR- Cas survives an initial phage or plasmid infection, it can acquire a short
DNA fragment, known as a ‘spacer,’ from the invading virus or plasmid. Once transcribed
and processed, this CRISPR spacer is used to guide a complex of Cas proteins to destroy
invading genetic elements that contain matching DNA sequences (Wiedenheft et al., 2012).
The decision of whether or not to maintain a CRISPR-Cas system depends on a balance of
factors that are just beginning to be understood and quantified. Enterococcus faecalis
represents an interesting example of how this bacterial calculus has been affected by the
antibiotic era. E. faecalis is a highly evolved inhabitant of the gastrointestinal (GI) tracts of
animals, from insects to man. In the complex milieu of the GI tract, there is a high
probability of encountering enterococcal phages and potentially other parasitic elements,
making CRISPR-mediated defense highly beneficial. However, CRISPR-Cas systems also
constitute an impediment to the entry of antibiotic resistance genes conveyed by mobile
elements, a barrier that is increasingly costly in the antibiotic era. As a result, a recent
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genomic study found that antibiotic resistance is concentrated in E. faecalis strains that have
lost CRISPR-Cas defense (Palmer and Gilmore, 2010). This loss of CRISPR-Cas has likely
had a profound effect on hospital-adapted E. faecalis strains, which now have genomes
about 25% larger than those of commensal strains, and are replete with plasmids, phages,
pathogenicity islands and other elements (Palmer et al., 2012). Undoubtedly this rapid
evolution of hospital isolates has been accompanied by fitness costs in a competitive
environment, but in a hospitalized patient treated with antibiotics, colonization by resistant
E. faecalis is largely non-competitive.
As Bikard et al., (2012) note, S. pneumoniae naturally lack CRISPR-Cas loci, whereas other
closely related, naturally transformable oral streptococci possess CRISPR-Cas. Given the
historic and landmark demonstrations by Griffith (1928) and Avery, MacLeod and McCarty
(1944) showing the importance of transformation for immune escape by S. pneumoniae, it
was of interest to determine whether selection for escape mutants is sufficient to explain the
absence of CRISPR-Cas in S. pneumoniae. Since no known S. pneumoniae strains contain
CRISPR-Cas systems, Bikard et al., (2012) grafted a functional CRISPR locus into S.
pneumoniae from the related species, S. pyogenes. They also engineered a S. pneumoniae
DNA donor to contain a sequence targeted by a S. pyogenes CRISPR spacer. This CRISPR-
Cas target sequence was placed adjacent to a selectable antibiotic resistance marker.
Showing that CRISPR-Cas blocks transformation in vitro, Bikard et al., (2012) found that
the transplanted CRISPR-Cas system prevents uptake of the resistance marker by S.
pneumoniae, but only when the donor harbors the adjacent perfect match to the CRISPR
spacer. Using very high levels of donor DNA, the investigators were able to obtain a few
antibiotic resistant transformants. Yet, these resistant transformants had loss of function
mutations in the CRISPR-Cas system or in the target sequence.
Having quantified the effect of CRISPR-Cas as an obstacle to transformation in vitro, it was
then of interest to determine whether CRISPR-Cas would block the capsule switching
observed by Griffith (1928) in vivo. Thus, Bikard et al., (2012) inserted a new spacer
element identical in sequence to a portion of a S. pneumoniae capsule gene into the grafted
CRISPR array. The experiments of Griffith (1928) were then repeated: mice were infected
with a mixture of heat-killed encapsulated S. pneumoniae and live, avirulent un-
encapsulated, S. pneumoniae. Differing from Griffth’s setup, the avirulent mice were now
CRISPR+ and loaded with a spacer from a capsule gene. Unlike Griffith’s experiments, the
mice survived, showing that CRISPR-Cas represents a barrier to capsule switching.
However, using higher levels of CRISPR-positive recipients and dead encapsulated donors,
a mouse was killed. As in the in vitro experiments, the escape mutant that acquired the
capsular genes and killed the mouse lacked a functional CRISPR-Cas system. This implies
that selection during the course of S. pneumoniae infection is strong enough to spur the
outgrowth of CRISPR-Cas defective mutants and may explain why S. pneumoniae natively
lack what appears to be a highly useful system to keep foreign DNA out.
For hospital adapted E. faecalis and S. pneumoniae, the need for genomic plasticity may
mean that the benefits of facile DNA uptake offset the fitness costs associated with lacking
CRISPR-Cas’ defenses. More generally, one can hypothesize that CRISPR-Cas’ frequency
in a species is shaped by the probability that a species encounters deleterious foreign DNA.
When incoming DNA is mainly harmful to the cell (e.g., lytic viruses), maintaining
CRISPR-Cas offers a large selective advantage. Conversely, when microbes require foreign
DNA to survive (e.g., under antibiotic targeting), CRISPR-Cas’ inhibition of horizontal gene
transfer is deleterious. Of course, this tug-of-war selecting for and against CRISPR-Cas may
be oversimplified. Some microbes might maintain CRISPR-Cas loci even when HGT is
beneficial. As in E. coli (Westra et al., 2010), organisms may do so by repressing their
CRISPR-Cas systems using genetic switches. When HGT suddenly becomes harmful, these
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silent loci could then be switched on to reap CRISPR-Cas’ benefits. A whole circuitry for
modulating CRISPR-Cas immunity may be ripe for discovery.
References
Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P.
CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007; 315:1709–
1712. [PubMed: 17379808]
Bikard D, Hatoum-Aslan A, Mucida D, Marraffin LM. CRISPR interference prevents horizontal gene
transfer during bacterial infection. Cell Host and Microbe, this issue. 2012
Griffith F. The Significance of Pneumococcal Types. The Journal of hygiene. 1928; 27:113–159.
[PubMed: 20474956]
Levin BR. Nasty viruses, costly plasmids, population dynamics, and the conditions for establishing
and maintaining CRISPR-mediated adaptive immunity in bacteria. PLoS Genet. 2010; 6:e1001171.
[PubMed: 21060859]
Marraffini LA, Sontheimer EJ. CRISPR interference limits horizontal gene transfer in staphylococci
by targeting DNA. Science. 2008; 322:1843–1845. [PubMed: 19095942]
Palmer KL, Gilmore MS. Multidrug-resistant enterococci lack CRISPR-cas. MBio 1. 2010
Palmer KL, Godfrey P, Griggs A, Kos VN, Zucker J, Desjardins C, Cerqueira G, Gevers D, Walker S,
Wortman J, et al. Comparative genomics of enterococci: variation in Enterococcus faecalis, clade
structure in E. faecium, and defining characteristics of E. gallinarum and E. casseliflavus. MBio.
2012; 3:e00318–00311. [PubMed: 22354958]
Westra ER, Pul U, Heidrich N, Jore MM, Lundgren M, Stratmann T, Wurm R, Raine A, Mescher M,
Van Heereveld L, et al. H-NS-mediated repression of CRISPR-based immunity in Escherichia coli
K12 can be relieved by the transcription activator LeuO. Mol Microbiol. 2010; 77:1380–1393.
[PubMed: 20659289]
Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and
archaea. Nature. 2012; 482:331–338. [PubMed: 22337052]
Weinberger and Gilmore Page 3














Top row: The seminal 1928 experiments of Griffith (1928), who found that injection of a
rough (un-encapsulated) strain of S. pneumoniae rarely killed mice (top left), whereas
injection of a smooth (encapsulated) strain did, and the smooth strain could be recovered
from the dead mouse. Injection of heat-killed encapsulated bacteria (grey smooth) did not
kill mice, but the combination of live rough S. pneumoniae together with heat-killed
encapsulated S. pneumoniae established a productive infection that killed the mice.
Moreover, when the bacteria recovered from the dead mice were cultured, they had
‘transformed’ from rough to smooth (Griffith, 1928). In the present work (Bikard et al.,
2012), Birkard and colleagues showed that if the rough strain carried a functional CRISPR-
Cas system that was designed to target a capsule gene, the transformation to smooth,
virulent S. pneumoniae was blocked. Further, these investigators showed that when they
forced the experiment using larger doses of bacteria, one mouse died and smooth bacteria
were in fact recovered. These bacteria had mutated their CRISPR-Cas system, rendering it
non-functional and unable to block the uptake of capsular DNA.
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